Cited by 1,254Diabetes Management and ResearchDiabetes Management and EducationDiabetes and associated disorders

The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.

Current State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic Registry

Miller, Kellee M., Foster, Nicole C., Beck, Roy W., Bergenstal, Richard M., DuBose, Stephanie N., DiMeglio, Linda A., Maahs, David M., Tamborlane, William V.·2015·Diabetes Care

DOI 10.2337/dc15-0078

Open this paper in CoChat — free account

Abstract

To examine the overall state of metabolic control and current use of advanced diabetes technologies in the U.S., we report recent data collected on individuals with type 1 diabetes participating in the T1D Exchange clinic registry. Data from 16,061 participants updated between 1 September 2013 and 1 December 2014 were compared with registry enrollment data collected from 1 September 2010 to 1 August 2012. Mean hemoglobin A1c (HbA1c) was assessed by year of age from <4 to >75 years. The overall average HbA1c was 8.2% (66 mmol/mol) at enrollment and 8.4% (68 mmol/mol) at the most recent update. During childhood, mean HbA1c decreased from 8.3% (67 mmol/mol) in 2–4-year-olds to 8.1% (65 mmol/mol) at 7 years of age, followed by an increase to 9.2% (77 mmol/mol) in 19-year-olds. Subsequently, mean HbA1c values decline gradually until ∼30 years of age, plateauing at 7.5–7.8% (58–62 mmol/mol) beyond age 30 until a modest drop in HbA1c below 7.5% (58 mmol/mol) in those 65 years of age. Severe hypoglycemia (SH) and diabetic ketoacidosis (DKA) remain all too common complications of treatment, especially in older (SH) and younger patients (DKA). Insulin pump use increased slightly from enrollment (58–62%), and use of continuous glucose monitoring (CGM) did not change (7%). Although the T1D Exchange registry findings are not population based and could be biased, it is clear that there remains considerable room for improving outcomes of treatment of type 1 diabetes across all age-groups. Barriers to more effective use of current treatments need to be addressed and new therapies are needed to achieve optimal metabolic control in people with type 1 diabetes.

Integrity signals

Registry

Crossref · 10.2337/dc15-0078

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview
Nathan, D. M., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2112 · Cited by 1,832
Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial
(1994) · The Journal of Pediatrics · doi:10.1016/s0022-3476(94)70190-3 · Cited by 1,654
Continuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.287.19.2563 · Cited by 941
Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes
Bergenstal, R. M., Tamborlane, W. V., Ahmann, A., Buse, J. B., Dailey, G., Davis, S. N., Joyce, C., Peoples, T., Perkins, B. A., Welsh, J. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002853 · Cited by 894
The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study
SEARCH for Diabetes in Youth Study Group (2006) · Pediatrics · doi:10.1542/peds.2006-0690 · Cited by 726
The Burden of Diabetes Mellitus Among US Youth: Prevalence Estimates From the SEARCH for Diabetes in Youth Study
Stockman, J. A. (2008) · Yearbook of Pediatrics · doi:10.1016/s0084-3954(08)70503-7 · Cited by 595
Evidence of a strong association between frequency of self-monitoring of blood glucose and hemoglobin A1c levels in T1D exchange clinic registry participants
Miller, K. M., Beck, R. W., Bergenstal, R. M., Goland, R. S., Haller, M. J., McGill, J. B., Rodriguez, H., Simmons, J. H., Hirsch, I. B., & for the T1D Exchange Clinic Network (2013) · Diabetes Care · doi:10.2337/dc12-1770 · Cited by 505
Self-citation
The T1D exchange clinic registry
Beck, R. W., Tamborlane, W. V., Bergenstal, R. M., Miller, K. M., DuBose, S. N., Hall, C. A., & for the T1D Exchange Clinic Network (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1561 · Cited by 456
Self-citation
Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality
Orchard, T. J., Nathan, D. M., Zinman, B., Cleary, P., Brillon, D., Backlund, J.-Y. C., & Lachin, J. M. (2015) · JAMA · doi:10.1001/jama.2014.16107 · Cited by 437

Flagged first, then by citations

Show all 25 references

1 of the 25 references couldn’t be matched to a known paper.

Sorted by citations

State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018
Foster, N. C., Beck, R. W., Miller, K. M., Clements, M. A., Rickels, M. R., DiMeglio, L. A., Maahs, D. M., Tamborlane, W. V., Bergenstal, R., Smith, E., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0384 · Cited by 1,907
Self-citation
An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes
Herold, K. C., Bundy, B. N., Long, S. A., Bluestone, J. A., DiMeglio, L. A., Dufort, M. J., Gitelman, S. E., Gottlieb, P. A., Krischer, J. P., Linsley, P. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1902226 · Cited by 1,189
“Three participants in the teplizumab group and 4 participants in the placebo group did not complete the trial regimen; the reasons were laboratory abnormalities (4 participants), an inability to have intravenous access established (2), or rash (1).”
Self-citation
Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial
Beck, R. W., Riddlesworth, T., Ruedy, K., Ahmann, A., Bergenstal, R., Haller, S., Kollman, C., Kruger, D., McGill, J. B., Polonsky, W., et al. (2017) · JAMA · doi:10.1001/jama.2016.19975 · Cited by 1,185
Self-citation
Type 1 diabetes immunotherapy using polyclonal regulatory T cells
Bluestone, J. A., Buckner, J. H., Fitch, M., Gitelman, S. E., Gupta, S., Hellerstein, M. K., Herold, K. C., Lares, A., Lee, M. R., Li, K., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aad4134 · Cited by 1,033
Continuous Glucose Monitoring: A Review of Successes, Challenges, and Opportunities
Rodbard, D. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0417 · Cited by 768
Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring
Bergenstal, R. M., Beck, R. W., Close, K. L., Grunberger, G., Sacks, D. B., Kowalski, A., Brown, A. S., Heinemann, L., Aleppo, G., Ryan, D. B., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1581 · Cited by 684
Self-citation
Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors
Rosenstock, J., & Ferrannini, E. (2015) · Diabetes Care · doi:10.2337/dc15-1380 · Cited by 664
Phase 3 trial of transplantation of human islets in type 1 diabetes complicated by severe hypoglycemia
Hering, B. J., Clarke, W. R., Bridges, N. D., Eggerman, T. L., Alejandro, R., Bellin, M. D., Chaloner, K., Czarniecki, C. W., Goldstein, J. S., Hunsicker, L. G., et al. (2016) · Diabetes Care · doi:10.2337/dc15-1988 · Cited by 645
Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes
Garg, S. K., Weinzimer, S. A., Tamborlane, W. V., Buckingham, B. A., Bode, B. W., Bailey, T. S., Brazg, R. L., Ilany, J., Slover, R. H., Anderson, S. M., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0421 · Cited by 585
Self-citation
Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline
LeRoith, D., Biessels, G. J., Braithwaite, S. S., Casanueva, F. F., Draznin, B., Halter, J. B., Hirsch, I. B., McDonnell, M. E., Molitch, M. E., Murad, M. H., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00198 · Cited by 616
Type 1 Diabetes in Children and Adolescents: A Position Statement by the American Diabetes Association
Chiang, J. L., Maahs, D. M., Garvey, K. C., Hood, K. K., Laffel, L. M., WEINZIMER, S. A., Wolfsdorf, J. I., & Schatz, D. (2018) · Diabetes Care · doi:10.2337/dci18-0023 · Cited by 565
Self-citation
ISPAD Clinical Practice Consensus Guidelines 2018: Glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes
DiMeglio, L. A., Acerini, C. L., Codner, E., Craig, M. E., Hofer, S. E., Pillay, K., & Maahs, D. M. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12737 · Cited by 604
Self-citation
Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials
Weisman, A., Bai, J.-W., Cardinez, M., Kramer, C. K., & Perkins, B. A. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30167-5 · Cited by 463
Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial
Tauschmann, M., Thabit, H., Bally, L., Allen, J. M., Hartnell, S., Wilinska, M. E., Ruan, Y., Sibayan, J., Kollman, C., Cheng, P., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31947-0 · Cited by 440
Self-citation
Effects of sotagliflozin added to insulin in patients with type 1 diabetes
Garg, S. K., Henry, R. R., Banks, P., Buse, J. B., Davies, M. J., Fulcher, G. R., Pozzilli, P., Gesty-Palmer, D., Lapuerta, P., Simó, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708337 · Cited by 417
Standardizing clinically meaningful outcome measures beyond HbA1c for type 1 diabetes: a consensus report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange
Agiostratidou, G., Anhalt, H., Ball, D., Blonde, L., Gourgari, E., Harriman, K. N., Kowalski, A. J., Madden, P., McAuliffe-Fogarty, A. H., McElwee-Malloy, M., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1624 · Cited by 397
Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial
van Beers, C. A. J., DeVries, J. H., Kleijer, S. J., Smits, M. M., Geelhoed-Duijvestijn, P. H., Kramer, M. H. H., Diamant, M., Snoek, F. J., & Serné, E. H. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30193-0 · Cited by 386
American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of SGLT-2 Inhibitors and Diabetic Ketoacidosis
Handelsman, Y., Henry, R. R., Bloomgarden, Z. T., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Ferrannini, E., Fonseca, V. A., Garber, A. J., Grunberger, G., et al. (2016) · Endocrine Practice · doi:10.4158/ep161292.ps · Cited by 358
Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial
Mathieu, C., Zinman, B., Hemmingsson, J. U., Woo, V., Colman, P., Christiansen, E., Linder, M., Bode, B., & for the ADJUNCT ONE Investigators (2016) · Diabetes Care · doi:10.2337/dc16-0691 · Cited by 347
REPLACE-BG: a randomized trial comparing continuous glucose monitoring with and without routine blood glucose monitoring in adults with well-controlled type 1 diabetes
Aleppo, G., Ruedy, K. J., Riddlesworth, T. D., Kruger, D. F., Peters, A. L., Hirsch, I., Bergenstal, R. M., Toschi, E., Ahmann, A. J., Shah, V. N., et al. (2017) · Diabetes Care · doi:10.2337/dc16-2482 · Cited by 329
Self-citation
Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials
Rosenstock, J., Marquard, J., Laffel, L. M., Neubacher, D., Kaspers, S., Cherney, D. Z., Zinman, B., Skyler, J. S., George, J., Soleymanlou, N., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1749 · Cited by 363
Diabetes Device Use in Adults With Type 1 Diabetes: Barriers to Uptake and Potential Intervention Targets
Tanenbaum, M. L., Hanes, S. J., Miller, K. M., Naranjo, D., Bensen, R., & Hood, K. K. (2017) · Diabetes Care · doi:10.2337/dc16-1536 · Cited by 296
Self-citation
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial
Dandona, P., Mathieu, C., Phillip, M., Hansen, L., Griffen, S. C., Tschöpe, D., THOREN, F. A., Xu, J. L., Langkilde, A. M., Proietto, J., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30308-x · Cited by 299
American Association of Clinical Endocrinology clinical practice guideline: the use of advanced technology in the management of persons with diabetes mellitus
Grunberger, G., Sherr, J., Allende, M., Blevins, T., Bode, B., Handelsman, Y., Hellman, R., Lajara, R., Roberts, V. L., Rodbard, D., et al. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.04.008 · Cited by 288
Machine learning in clinical decision making
Adlung, L., Cohen, Y., Mor, U., & Elinav, E. (2021) · Med · doi:10.1016/j.medj.2021.04.006 · Cited by 321
Efficacy and Safety of Canagliflozin, a Sodium–Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes
Henry, R. R., Thakkar, P., Tong, C., Polidori, D., & Alba, M. (2015) · Diabetes Care · doi:10.2337/dc15-1730 · Cited by 286
Multicenter trial of a tubeless, on-body automated insulin delivery system with customizable glycemic targets in pediatric and adult participants with type 1 diabetes
Brown, S. A., Forlenza, G. P., Bode, B. W., Pinsker, J. E., Levy, C. J., Criego, A. B., Hansen, D. W., Hirsch, I. B., Carlson, A. L., Bergenstal, R. M., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0172 · Cited by 286
Self-citation
Transplantation of chemically induced pluripotent stem-cell-derived islets under abdominal anterior rectus sheath in a type 1 diabetes patient.
Wang, S., Du, Y., Zhang, B., Meng, G., Liu, Z., Liew, S. Y., Liang, R., Zhang, Z., Cai, X., Wu, S., et al. (2024) · Cell · doi:10.1016/j.cell.2024.09.004 · Cited by 281
Management of Hyperglycemic Crises
Fayfman, M., Pasquel, F. J., & Umpierrez, G. E. (2017) · Medical Clinics of North America · doi:10.1016/j.mcna.2016.12.011 · Cited by 312
Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: The adjunct two randomized trial
Ahrén, B., Hirsch, I. B., Pieber, T. R., Mathieu, C., Gómez-Peralta, F., Hansen, T. K., Philotheou, A., Birch, S., Christiansen, E., Jensen, T. J., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0690 · Cited by 262
Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial
El-Khatib, F. H., BALLIRO, C. A., HILLARD, M. A., Magyar, K. L., Ekhlaspour, L., Sinha, M., Mondesir, D., Esmaeili, A., Hartigan, C., Thompson, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32567-3 · Cited by 265
Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial
Mathieu, C., Dandona, P., Gillard, P., Senior, P., Hasslacher, C., Araki, E., Lind, M., Bain, S. C., Jabbour, S., Arya, N., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0623 · Cited by 252
Incidence and prevalence of diabetic ketoacidosis (DKA) among adults with type 1 diabetes mellitus (T1D): a systematic literature review
FARSANI, S. F. F., Brodovicz, K. G., Soleymanlou, N., Marquard, J., Wissinger, E., & Maiese, B. A. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-016587 · Cited by 252
“Several publications (for example, those based on the T1D Exchange Clinic Registry 11 22 29 33 36–38 ) relied on patient recall of past DKA events.”
Method
Predictive low-glucose suspend reduces hypoglycemia in adults, adolescents, and children with type 1 diabetes in an at-home randomized crossover study: results of the PROLOG trial
Forlenza, G. P., Li, Z., Buckingham, B. A., Pinsker, J. E., Cengiz, E., Wadwa, R. P., Ekhlaspour, L., Church, M. M., Weinzimer, S. A., Jost, E., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0771 · Cited by 246
“ticipants using an insulin pump and CGM before the study were higher and baseline HbA1c levels were lower than the national averages for adults and children with type 1 diabetes (9).”
BackgroundInfluentialSelf-citation
Advances in technology for management of type 1 diabetes
Beck, R. W., Bergenstal, R. M., Laffel, L. M., & Pickup, J. C. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31142-0 · Cited by 242
Self-citation
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study
Dandona, P., Mathieu, C., Phillip, M., Hansen, L., Tschöpe, D., Thorén, F., Xu, J., Langkilde, A. M., DEPICT-1 Investigators, Proietto, J., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1087 · Cited by 243
Self-citation
Insulin dose optimization using an automated artificial intelligence-based decision support system in youths with type 1 diabetes
Nimri, R., Battelino, T., Laffel, L. M., Slover, R. H., Schatz, D., Weinzimer, S. A., Dovc, K., Danne, T., Phillip, M., NextDREAM Consortium, et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1045-7 · Cited by 242
Wearable Continuous Glucose Monitoring Sensors: A Revolution in Diabetes Treatment
Cappon, G., Acciaroli, G., Vettoretti, M., Facchinetti, A., & Sparacino, G. (2017) · Electronics · doi:10.3390/electronics6030065 · Cited by 247
Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the North American inTandem1 Study
Buse, J. B., Garg, S. K., Rosenstock, J., Bailey, T. S., Banks, P., Bode, B. W., Danne, T., Kushner, J. A., Lane, W. S., Lapuerta, P., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0343 · Cited by 234
Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes
Carlson, A. L., Sherr, J. L., Shulman, D. I., Garg, S. K., Pop-Busui, R., Bode, B. W., Lilenquist, D. R., Brazg, R. L., Kaiserman, K. B., Kipnes, M. S., et al. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0319 · Cited by 230
Continuous glucose monitoring and glycemic control among youth with type 1 diabetes: International comparison from the T1D Exchange and DPV Initiative
DeSalvo, D. J., Miller, K. M., Hermann, J. M., Maahs, D. M., Hofer, S. E., Clements, M. A., Lilienthal, E., Sherr, J. L., Tauschmann, M., Holl, R. W., et al. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12711 · Cited by 233
Self-citation
The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes
Dong, S., Hiam-Galvez, K. J., Mowery, C. T., Herold, K. C., Gitelman, S. E., Esensten, J. H., Liu, W., Lares, A., Leinbach, A., Lee, M., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.147474 · Cited by 232
“The disease pathogenesis, which is influenced by genetic and environmental factors, is attributed to the loss of immune tolerance which results in the development and inadequate control of pathogenic auto-reactive T cells that recognize and destroy islet beta cells (1-3).”
BackgroundMethod
Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: a 12-week multicentre, open-label randomised controlled crossover trial
Benhamou, P.-Y., Franc, S., Reznik, Y., Thivolet, C., Schaepelynck, P., Renard, E., Guerci, B., Chaillous, L., Lukas-Croisier, C., Jeandidier, N., et al. (2019) · The Lancet Digital Health · doi:10.1016/s2589-7500(19)30003-2 · Cited by 217
Outcome measures for artificial pancreas clinical trials: a consensus report
Maahs, D. M., Buckingham, B. A., Castle, J. R., Cinar, A., Damiano, E. R., Dassau, E., DeVries, J. H., Doyle, F. J., Griffen, S. C., Haidar, A., et al. (2016) · Diabetes Care · doi:10.2337/dc15-2716 · Cited by 211
Self-citation
Longitudinal Trends in Glycemic Outcomes and Technology Use for Over 48,000 People with Type 1 Diabetes (2016–2022) from the T1D Exchange Quality Improvement Collaborative
Ebekozien, O. A., Mungmode, A., Sanchez, J. E., Rompicherla, S., Demeterco‐Berggren, C., Weinstock, R. S., Jacobsen, L. M., Davis, G. M., McKee, A. M., Aktürk, H. K., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0320 · Cited by 214
“2,4,7,10,15 In 2016, T1DX-Research centers were invited to participate in the T1DX-QI.”
Self-citation
ISPAD Clinical Practice Consensus Guidelines 2018: diabetes technologies
Sherr, J. L., Tauschmann, M., Battelino, T., de Bock, M., Forlenza, G., Roman, R., Hood, K. K., & Maahs, D. M. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12731 · Cited by 197
Self-citation
Continuous glucose monitoring: a consensus conference of the American Association of Clinical Endocrinologists and American College of Endocrinology
Fonseca, V. A., Grunberger, G., Anhalt, H., Bailey, T. S., Blevins, T., Garg, S. K., Handelsman, Y., Hirsch, I. B., Orzeck, E. A., Roberts, V. L., et al. (2016) · Endocrine Practice · doi:10.4158/ep161392.cs · Cited by 195
“The number of users in the T1D Exchange clinic registry has more than doubled to 15% in 2016 (1,25,26), and observational data collected in 2014-2015 from the T1D Exchange clinic registry support the benefits of newer devices.”
Background
Racial-Ethnic Inequity in Young Adults With Type 1 Diabetes
Agarwal, S., Kanapka, L. G., Raymond, J. K., Walker, A., Gerard-Gonzalez, A., Kruger, D., Redondo, M. J., Rickels, M. R., Shah, V. N., Butler, A., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa236 · Cited by 205
“Minority YA groups exhibit some of the highest HbA1c levels, rates of hospitalizations, psychiatric comorbidity, and mortality among all age groups with type 1 diabetes, highlighting major racial-ethnic disparity in outcomes (4-9).”
Background
Temporal Trends and Contemporary Use of Insulin Pump Therapy and Glucose Monitoring Among Children, Adolescents, and Adults With Type 1 Diabetes Between 1995 and 2017
van den Boom, L., Karges, B., Auzanneau, M., Rami-Merhar, B., Lilienthal, E., von Sengbusch, S., Datz, N., Schröder, C., Kapellen, T., Laimer, M., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0345 · Cited by 191
HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study
Danne, T., Cariou, B., Banks, P. L., Brändle, M., Brath, H., Franek, E., Kushner, J. A., Lapuerta, P., McGuire, D. K., Peters, A. L., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0342 · Cited by 187
Closed-Loop Control During Intense Prolonged Outdoor Exercise in Adolescents With Type 1 Diabetes: The Artificial Pancreas Ski Study
Breton, M. D., Cherñavvsky, D. R., Forlenza, G. P., DeBoer, M. D., Robic, J., Wadwa, R. P., Messer, L. H., Kovatchev, B. P., & Maahs, D. M. (2017) · Diabetes Care · doi:10.2337/dc17-0883 · Cited by 179
Self-citation
Safety Evaluation of the MiniMed 670G System in Children 7–13 Years of Age with Type 1 Diabetes
Forlenza, G. P., Pinhas‐Hamiel, O., Liljenquist, D. R., Shulman, D. I., Bailey, T. S., Bode, B. W., Wood, M. A., Buckingham, B. A., Kaiserman, K. B., Shin, J., et al. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0264 · Cited by 184
A Mobile App for the Self-Management of Type 1 Diabetes Among Adolescents: A Randomized Controlled Trial
Goyal, S., Nunn, C. A., Rotondi, M., Couperthwaite, A. B., Reiser, S., Simone, A., Katzman, D. K., Cafazzo, J. A., & Palmert, M. R. (2017) · JMIR mHealth and uHealth · doi:10.2196/mhealth.7336 · Cited by 146
“Adolescents, in particular, struggle with optimizing blood glucose control, with worldwide data indicating they consistently fail to meet their prescribed therapeutic targets [7,8].”
Diagnosis and treatment of type 1 diabetes at the dawn of the personalized medicine era
Akil, A. A., Yassin, E., Al-Maraghi, A., ALIYEV, E. E., Al-Malki, K., & Fakhro, K. A. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02778-6 · Cited by 215
“Briefly, the algorithm offers weekly insulin dosage recommendations for adult patients with T1D using multiple daily injections protocol of longacting basal and short-acting bolus insulin [108].”
Background
Fear of hypoglycemia in adults with type 1 diabetes: impact of therapeutic advances and strategies for prevention - a review
Martyn-Nemeth, P. A., Farabi, S. S., Mihailescu, D. V., Nemeth, J., & Quinn, L. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.09.003 · Cited by 168
“Population data from the Type 1 Diabetes Exchange clinic registry reported that only 14% of those aged 18–25 years and 29% aged 26–50 years achieved an A1C less than 7% (Miller et al., 2015).”
Accuracy of a 14-Day Factory-Calibrated Continuous Glucose Monitoring System With Advanced Algorithm in Pediatric and Adult Population With Diabetes
Alva, S., Bailey, T., Brazg, R., Budiman, E. S., Castorino, K., Christiansen, M. P., Forlenza, G., Kipnes, M., Liljenquist, D. R., & Liu, H. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820958754 · Cited by 164
The challenge of modulating β-cell autoimmunity in type 1 diabetes
Atkinson, M. A., Roep, B. O., Posgai, A. L., Wheeler, D. C. S., & Peakman, M. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30112-8 · Cited by 161
An artificial intelligence decision support system for the management of type 1 diabetes
Tyler, N. S., MOSQUERA-LOPEZ, C. M., Wilson, L. M., Dodier, R. H., Branigan, D. L., Gabo, V. B., Guillot, F. H., Hilts, W. W., Youssef, J. E., Castle, J. R., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0212-y · Cited by 171
“The mutual information between two random variables (for example, a feature f with a distribution F and a recommendation r with a distribution R) with a joint probability mass function (PFR) is defined according to equation (2).”
BackgroundMethod
Incidences of Severe Hypoglycemia and Diabetic Ketoacidosis and Prevalence of Microvascular Complications Stratified by Age and Glycemic Control in U.S. Adult Patients With Type 1 Diabetes: A Real-World Study
Pettus, J., Zhou, F. L., Shepherd, L. C., Preblick, R., Hunt, P. R., Paranjape, S., Miller, K. M., & Edelman, S. V. (2019) · Diabetes Care · doi:10.2337/dc19-0830 · Cited by 162
Self-citation
HbA1c Levels in Type 1 Diabetes from Early Childhood to Older Adults: A Deeper Dive into the Influence of Technology and Socioeconomic Status on HbA1c in the T1D Exchange Clinic Registry Findings
Miller, K. M., Beck, R. W., Foster, N. C., Maahs, D. M., & Exchange, F. T. T. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0393 · Cited by 162
Self-citation
ISPAD Clinical Practice Consensus Guidelines 2018: Diabetes in adolescence
Cameron, F. J., Garvey, K. C., Hood, K. K., Acerini, C. L., & Ethel Codner, D. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12702 · Cited by 163
“of improved blood glucose control and reduced hypoglycemia frequency,(67) but is only observed in those patients who maintain strict adherence with the treatment regimen.(63,68) Interestingly although, and against the overall trend in pediatric control, in one large survey of Swedish, German, and Austrian adolescents…”
Background
An alternative sensor-based method for glucose monitoring in children and young people with diabetes
Edge, J., Acerini, C. L., Campbell, F., Hamilton-Shield, J. P., Moudiotis, C., Rahman, S., Randell, T. L., Smith, A., & Trevelyan, N. (2017) · Archives of Disease in Childhood · doi:10.1136/archdischild-2016-311530 · Cited by 155
Randomized Outpatient Trial of Single- and Dual-Hormone Closed-Loop Systems That Adapt to Exercise Using Wearable Sensors
Castle, J. R., El Youssef, J., Wilson, L. M., Reddy, R., Resalat, N., Branigan, D., Ramsey, K., Leitschuh, J., Rajhbeharrysingh, U., Senf, B., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0228 · Cited by 152
Prevalence of Celiac Disease in 52,721 Youth With Type 1 Diabetes: International Comparison Across Three Continents
Craig, M. E., Prinz, N., Boyle, C. T., Campbell, F. M., Jones, T. W., Hofer, S. E., Simmons, J. H., Holman, N., Tham, E., Fröhlich-Reiterer, E., et al. (2017) · Diabetes Care · doi:10.2337/dc16-2508 · Cited by 146
Self-citation
Management of Type 1 Diabetes With a Very Low–Carbohydrate Diet
Lennerz, B. S., Barton, A. B., Bernstein, R. K., Dikeman, R. D., Diulus, C. A., Hallberg, S. J., Rhodes, E. T., Ebbeling, C. B., Westman, E. C., Yancy, W. S., et al. (2018) · PEDIATRICS · doi:10.1542/peds.2017-3349 · Cited by 149
The Artificial Pancreas: How Closed-Loop Control Is Revolutionizing Diabetes
Haidar, A. (2016) · IEEE Control Systems · doi:10.1109/mcs.2016.2584318 · Cited by 145
Stress and A1c Among People with Diabetes Across the Lifespan
Hilliard, M. E., Yi‐Frazier, J. P., Hessler, D., Butler, A. M., Anderson, B. J., & Jaser, S. S. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0761-3 · Cited by 149
Increased Time in Range and Fewer Missed Bolus Injections After Introduction of a Smart Connected Insulin Pen
Adolfsson, P., Hartvig, N. V., Kaas, A., Møller, J. B., & Hellman, J. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0411 · Cited by 139
“CGM, including isCGM (hereafter, unless stated, CGM includes both rtCGM and isCGM), is being used by an increasing number of people with type 1 diabetes (T1D).(15,16) The key benefits of CGM include real‐time data monitoring for people with T1D and access for them and their HCPs to complete glucose datasets;(17) both…”
Method
Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial
Todd, J. A., Evangelou, M., Cutler, A. J., Pękalski, M. Ł., Walker, N. M., Stevens, H. E., Porter, L., Smyth, D. J., Rainbow, D. B., Ferreira, R. C., et al. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002139 · Cited by 138
“The result is a lifelong requirement for intensive insulin treatment that increases the risk of hypoglycaemia and stops the majority of patients from achieving adequate metabolic control to prevent the long-term complications of retinopathy, neuropathy, and/or nephropathy [2,3].”
Six months of hybrid closed loop in the real‐world: An evaluation of children and young adults using the 670G system
Berget, C., Messer, L. H., Vigers, T., Frohnert, B. I., Pyle, L. L., Wadwa, R. P., Driscoll, K. A., & Forlenza, G. P. (2019) · Pediatric Diabetes · doi:10.1111/pedi.12962 · Cited by 138
“This improvement in HbA1c is particularly remarkable as 37% of participants were 14-17 years of age, the age range when HbA1c tends to be the highest.(3,7) Notably, the participants with the highest baseline HbA1c experienced the greatest decline in HbA1c after 6 months of Auto Mode use.”
Background
A Novel Dual-Hormone Insulin-and-Pramlintide Artificial Pancreas for Type 1 Diabetes: A Randomized Controlled Crossover Trial
Haidar, A., Tsoukas, M. A., Bernier-Twardy, S., Yale, J., Rutkowski, J., Bossy, A., Pytka, E., Fathi, A. E., Strauss, N., & Legault, L. (2020) · Diabetes Care · doi:10.2337/dc19-1922 · Cited by 149
Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC Study
Gubitosi‐Klug, R., Braffett, B. H., White, N. H., Sherwin, R. S., Service, F. J., Lachin, J. M., & Tamborlane, W. V. (2017) · Diabetes Care · doi:10.2337/dc16-2723 · Cited by 140
Self-citation
A Clinical Overview of Insulin Pump Therapy for the Management of Diabetes: Past, Present, and Future of Intensive Therapy
Berget, C., Messer, L. H., & Forlenza, G. P. (2019) · Diabetes Spectrum · doi:10.2337/ds18-0091 · Cited by 151
Psychometric Properties of the Problem Areas in Diabetes: Teen and Parent of Teen Versions
Shapiro, J. B., Vesco, A. T., Weil, L. E. G., Evans, M. A., Hood, K. K., & Weissberg-Benchell, J. A. (2017) · Journal of Pediatric Psychology · doi:10.1093/jpepsy/jsx146 · Cited by 139
“During adolescence, adherence, and parental monitoring for diabetes tasks declines (Main et al., 2014) and glycemic control worsens (Miller et al., 2015).”
BackgroundInfluential
Cost, Hassle, and On-Body Experience: Barriers to Diabetes Device Use in Adolescents and Potential Intervention Targets
Messer, L. H., Tanenbaum, M. L., Cook, P. F., Wong, J. J., Hanes, S. J., Driscoll, K. A., & Hood, K. K. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0509 · Cited by 131
Comparison of different treatment modalities for type 1 diabetes, including sensor-augmented insulin regimens, in 52 weeks of follow-up: A comisair study
Šoupal, J., Petruželková, L., Flekač, M., Pelcl, T., Matoulek, M., Daňková, M., Škrha, J., Svačina, Š., & Prázný, M. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0171 · Cited by 126
Optimizing Hybrid Closed-Loop Therapy in Adolescents and Emerging Adults Using the MiniMed 670G System
Messer, L. H., Forlenza, G. P., Sherr, J. L., Wadwa, R. P., Buckingham, B. A., WEINZIMER, S. A., Maahs, D. M., & Slover, R. H. (2018) · Diabetes Care · doi:10.2337/dc17-1682 · Cited by 126
Self-citation
American Association Of Clinical Endocrinologists And American College Of Endocrinology 2016 Outpatient Glucose Monitoring Consensus Statement
Bailey, T. S., Grunberger, G., Bode, B. W., Handelsman, Y., Hirsch, I. B., Jovanovič, L., Roberts, V. L., Rodbard, D., Tamborlane, W. V., & Walsh, J. S. A. (2016) · Endocrine Practice · doi:10.4158/ep151124.cs · Cited by 130
Self-citation
Insulin pump therapy in children with type 1 diabetes: analysis of data from the SWEET registry
Szypowska, A., Schwandt, A., Svensson, J., Shalitin, S., Cardona‐Hernandez, R., Forsander, G., Sundberg, F., de Beaufort, C. E., Maahs, D. M., Maffeis, C., et al. (2016) · Pediatric Diabetes · doi:10.1111/pedi.12416 · Cited by 126
“The prevalence of CSII therapy usage has increased in many countries, but there are still differences in CSII usage among countries.10 The overall use of insulin pumps in patients 0-18 y was 74% (2011) in Slovenia,7 and 58-65% (2015) in United States.15 The data from three large registries of pediatric type 1 diabetes…”
BackgroundInfluentialSelf-citation
SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: Balancing benefits and risks
Taylor, S. I., Blau, J. E., Rother, K. I., & Beitelshees, A. L. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30154-8 · Cited by 124
Effect of a Hybrid Closed-Loop System on Glycemic and Psychosocial Outcomes in Children and Adolescents With Type 1 Diabetes
Abraham, M. B., de Bock, M. I., Smith, G. J., Dart, J., Fairchild, J. M., King, B. R., Ambler, G. R., Cameron, F. J., McAuley, S. A., KEECH, A. C., et al. (2021) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2021.3965 · Cited by 128
Comparison of Insulin Glargine 300 Units/mL and 100 Units/mL in Adults With Type 1 Diabetes: Continuous Glucose Monitoring Profiles and Variability Using Morning or Evening Injections
Bergenstal, R. M., Bailey, T. S., Rodbard, D., Ziemen, M., Guo, H., Muehlen-Bartmer, I., & Ahmann, A. (2017) · Diabetes Care · doi:10.2337/dc16-0684 · Cited by 122
Self-citation
Continuous Glucose Monitoring: A Brief Review for Primary Care Practitioners
Ajjan, R., Slattery, D., & Wright, E. E. (2019) · Advances in Therapy · doi:10.1007/s12325-019-0870-x · Cited by 133
The Transatlantic HbA1c gap: differences in glycaemic control across the lifespan between people included in the US T1D Exchange Registry and those included in the German/Austrian DPV registry
Hermann, J. M., Miller, K. M., Hofer, S. E., Clements, M. A., Karges, W., Foster, N. C., Fröhlich-Reiterer, E. E., Rickels, M. R., Rosenbauer, J., DeSalvo, D. J., et al. (2019) · Diabetic Medicine · doi:10.1111/dme.14148 · Cited by 121
Self-citation
Recommendations for Using Real-Time Continuous Glucose Monitoring (rtCGM) Data for Insulin Adjustments in Type 1 Diabetes
Pettus, J., & Edelman, S. V. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816663747 · Cited by 122
“However, given the recent advances in the accuracy, reliability, and usability of rtCGM systems that have alerts and ROC arrows, many clinicians and patients feel strongly that SMBG does not provide adequate information to effectively manage insulintreated diabetes to avoid extreme hyperglycemia and safeguard against…”
Background
Navigating Two Roads to Glucose Normalization in Diabetes: Automated Insulin Delivery Devices and Cell Therapy
Latres, E., Finan, D. A., Greenstein, J. L., Kowalski, A. J., & Kieffer, T. J. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.02.007 · Cited by 124
Cost-effectiveness of Continuous Glucose Monitoring for Adults With Type 1 Diabetes Compared With Self-Monitoring of Blood Glucose: The DIAMOND Randomized Trial
Wan, W., Skandari, M. R., Minc, A., Nathan, A. G., Winn, A. N., Zarei, P., O’Grady, M. J., & Huang, E. S. (2018) · Diabetes Care · doi:10.2337/dc17-1821 · Cited by 126
Trends in emergency department visits and inpatient admissions for hyperglycemic crises in adults with diabetes in the U.S., 2006–2015
Benoit, S. R., Hora, I., Pasquel, F. J., Gregg, E. W., Albright, A. L., & Imperatore, G. (2020) · Diabetes Care · doi:10.2337/dc19-2449 · Cited by 117
Optimal use of diabetes devices: clinician perspectives on barriers and adherence to device use
Tanenbaum, M. L., Adams, R. N., Hanes, S. J., Barley, R. C., Miller, K. M., Mulvaney, S. A., & Hood, K. K. (2017) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816688010 · Cited by 117
Glycemic Control, Cardiac Autoimmunity, and Long-Term Risk of Cardiovascular Disease in Type 1 Diabetes Mellitus: A DCCT/EDIC Cohort–Based Study
Sousa, G. R., Pober, D., Galderisi, A., Lv, H., Yu, L., Pereira, A. C., Doria, A., Kosiborod, M., & Lipes, M. A. (2019) · Circulation · doi:10.1161/circulationaha.118.036068 · Cited by 117
Best friend or spy: a qualitative meta‐synthesis on the impact of continuous glucose monitoring on life with Type 1 diabetes
Messer, L. H., Johnson, R., Driscoll, K. A., & Jones, J. (2017) · Diabetic Medicine · doi:10.1111/dme.13568 · Cited by 124
PedsQL 3.2 Diabetes Module for Children, Adolescents, and Young Adults: Reliability and Validity in Type 1 Diabetes
Varni, J. W., Delamater, A. M., Hood, K. K., Raymond, J. K., CHANG, N. T., Driscoll, K. A., Wong, J. C., Yi‐Frazier, J. P., Grishman, E. K., Faith, M. A., et al. (2018) · Diabetes Care · doi:10.2337/dc17-2707 · Cited by 116
“Rates of insulin pump and continuous glucose monitor use in the sample are similar to published data from the T1D Exchange Clinic Registry (34), further supporting the representativeness of the sample.”
Result
Diabetes technology: improving care, improving patient‐reported outcomes and preventing complications in young people with Type 1 diabetes
Prahalad, P., Tanenbaum, M. L., Hood, K. K., & Maahs, D. M. (2018) · Diabetic Medicine · doi:10.1111/dme.13588 · Cited by 125
Self-citation
The Australasian Diabetes Data Network: first national audit of children and adolescents with type 1 diabetes
Phelan, H., Clapin, H. F., Bruns, L., Cameron, F. J., Cotterill, A. M., Couper, J., Davis, E. A., Donaghue, K. C., Jefferies, C., King, B. R., et al. (2017) · The Medical Journal of Australia · doi:10.5694/mja16.00737 · Cited by 113
Preserving Skin Integrity with Chronic Device Use in Diabetes
Messer, L. H., Berget, C., Beatson, C. R., Polsky, S., & Forlenza, G. P. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0080 · Cited by 113
Sleep in children with type 1 diabetes and their parents in the T1D Exchange
Jaser, S. S., Foster, N. C., Nelson, B., Kittelsrud, J. M., DiMeglio, L. A., Quinn, M., Willi, S. M., & Simmons, J. H. (2017) · Sleep Medicine · doi:10.1016/j.sleep.2017.07.005 · Cited by 112
Self-citation
Diabetes Technology
Naranjo, D. M., Tanenbaum, M. L., Iturralde, E., & Hood, K. K. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816650900 · Cited by 111
“In terms of CGM and health outcomes, 3 pivotal trials – the JDRF CGM randomized controlled trial,(13) Guard Control Study,(26) and O’Connell and colleagues(27) – demonstrated that adults on CGM had better A1C than blood glucose monitoring alone without an increase of hypoglycemic episodes,(28) as well as a lower frequ…”
BackgroundInfluential
Strategy for mitigating DKA risk in patients with type 1 diabetes on adjunctive treatment with SGLT inhibitors: A STICH protocol
Garg, S. K., Peters, A. L., Buse, J. B., & Danne, T. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0246 · Cited by 108
“In the emergency department, the same protocol involving carbohydrates, ﬂuids, and insulin should be used to treat DKA.”
Influential
Diabetes distress is more strongly associated with HbA1c than depressive symptoms in adolescents with type 1 diabetes: Results from Diabetes MILES Youth-Australia
Hagger, V. L., Hendrieckx, C., Cameron, F. J., Pouwer, F., Skinner, T. C., & Speight, J. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12641 · Cited by 115
Clostridium butyricum CGMCC0313.1 Protects against Autoimmune Diabetes by Modulating Intestinal Immune Homeostasis and Inducing Pancreatic Regulatory T Cells
Jia, L., Shan, K., Pan, L., Feng, N., Lv, Z., Sun, Y., Li, J., Wu, C., Zhang, H., Chen, W., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01345 · Cited by 106

Authors: Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V.
Affiliations: Jaeb Center for Health Research (US)
Park Nicollet Health Services (US)
Indiana University School of Medicine (US)
Barbara Davis Center for Childhood Diabetes, Aurora, CO
Yale University (US)
Corresponding author: Miller, Kellee M.
ORCID: Miller, Kellee M.
Foster, Nicole C.
Beck, Roy W.
Bergenstal, Richard M.
DuBose, Stephanie N.
DiMeglio, Linda A.
Maahs, David M.
Tamborlane, William V.
Venue: Diabetes Care
Publisher: American Diabetes Association
Published: 2015-05-12
Volume: 38
Issue: 6
Pages: 971-978
ISSN: 0149-5992 (ISSN-L)
1935-5548
DOI: 10.2337/dc15-0078
OpenAlex: W2098570086
Cited by: 1,254
References: 25
Citations by year: 2026: 35 · 2025: 55 · 2024: 64 · 2023: 88 · 2022: 81 · 2021: 134 · 2020: 157 · 2019: 198 · 2018: 176 · 2017: 138 · 2016: 108 · 2015: 19
FWCI: 127.79
Type: journal article
Language: en
Open access: closed
Licence: www.diabetesjournals.org/site/license (vor, 203 d)
Locations: Diabetes Care (publishedVersion)
PubMed (publishedVersion)
Funders: Leona M. and Harry B. Helmsley Charitable Trust
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
Keywords: type 1 diabetes, glycemic control, HbA1c, severe hypoglycemia, diabetic ketoacidosis, insulin pump therapy, continuous glucose monitoring, diabetes technology, age trends
MeSH terms: Adolescent, Adult, Aged, Child, Child, Preschool, Diabetes Mellitus, Type 1, Health Services Needs and Demand, Glycated Hemoglobin, Humans, Insulin Infusion Systems, Male, Middle Aged, Registries, United States, Blood Glucose Self-Monitoring, Comorbidity, Diabetic Ketoacidosis, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Current State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic Registry

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Citations

Cites

Cited by

Related

Metadata

Record

About these checks